drugset / Trial / NCT03193593

Study to Evaluate EB-001 in Reducing Musculoskeletal Pain

NCT03193593 ↗

Phase 2 Completed 66 enrolled Bonti, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

To determine the safety and efficacy of single intra-operative treatment of EB-001 IM injections into the Pectoralis Major (PM) in subjects undergoing breast augmentation with subpectoral implants

Timeline

Start
2017-08-29
Primary completion
2018-04-26
Completion
2018-08-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator EB-001 Protein / enzyme biologic — Intramuscular